RGA’s Q1 Momentum Stems From Global In‑Force Wins and Favorable Claims, but Capital Deployment Remains a Test

Tony Cheng, RGA’s president and chief executive, opened the call by framing the quarter as “a strong start to the year with excellent performance across many regions and businesses.” The numbers backed that narrative. Adjusted operating income rose to $611 million, translating to $6.97 per share after tax, while the trailing twelve‑month adjusted return on equity, stripped of notable items, held at 16.2%.

Those results sit atop a 5% year‑over‑year premium growth in the traditional business, buoyed by “good growth across EMEA and APAC,” Cheng said, while U.S. traditional premiums edged up only 1% after a 2025 strategic recapture of lower‑quality blocks.

Geography proved the most vivid differentiator. In Asia‑Pacific, RGA “closed a number of notable transactions … in Japan, spanning both in‑force and flow deals that include both asset and biometric risk,” Cheng noted, highlighting the firm’s ability to pair reinsurance capital with its asset‑management expertise.

EMEA’s earnings “exceeded expectations,” driven by “favorable overall experience and continued momentum in longevity.” The U.S., meanwhile, delivered “strong adjusted operating performance … supported by favorable claims experience and the contribution from recent new business,” though the traditional segment’s modest premium growth left analysts probing the durability of that trend.

Claims experience emerged as a recurring theme. Axel Philippe André, chief financial officer, quantified the quarter’s economic biometric claims advantage at $117 million, with a $4 million current‑period financial impact. “Over half of the economic experience was driven by U.S.

individual life, and every region had favorable experience,” he said. Since the start of 2023, the cumulative economic claim benefit sits at $343 million, a tail that will be recognized gradually – André estimated roughly $20 million a year over the next twelve months.

Investment income, however, fell short of internal expectations. RGA assumed a 7% variable investment return for the year, “below our longer‑term expectations of 10% to 12%,” André explained, citing a muted real‑estate market that delays income recognition.

The non‑spread book yield, excluding variable income, held at 4.85%, while the new‑money rate dipped to 5.64% as the firm shifted toward high‑quality public corporates. Private credit, representing about 9% of the total portfolio, remained “highly diversified” and “in line with expectations,” providing an illiquidity premium without compromising the overall credit quality.

Capital management featured prominently. RGA repurchased $50 million of stock in the quarter, bringing total buybacks to $175 million since the program’s reinstatement in Q3 2025. The firm ended the quarter with an estimated $2.4 billion of excess capital and $2.9 billion of deployable capital over the next twelve months. Management reiterated its long‑term target of returning 20%‑30% of after‑tax operating earnings to shareholders and pledged $400 million of excess capital to reduce leverage in 2026.

Analysts pressed the leadership on whether the pipeline could absorb the “$1 billion of deployment needed to hit the 8%‑10% EPS growth” they have heard in prior guidance. André responded that capital deployment was “right in line with our expectations” and emphasized quality over quantity. The question of concentration risk surfaced when Suneet Kamath of Jefferies asked about the Equitable transaction amid the pending Corebridge merger. André brushed off any material impact, noting the partnership remains strong.

Mortality trends also attracted attention. UBS’s analyst queried the “surprisingly favorable” U.S. mortality experience. Chief risk officer Jonathan William Porter pointed to a “lower frequency of claims, both large and non‑large” and a moderate flu season, while acknowledging that GLP‑1 therapies could further improve future mortality assumptions, though no changes have been incorporated yet.

Seasonality under the new LDTI accounting regime was another focus. A Wells Fargo analyst asked whether Q1 still lags the rest of the year. Porter explained that the company’s reserves already embed a higher Q1 claims expectation, and LDTI should “partially offset” any seasonal swing, especially for uncapped cohorts.

Regulatory chatter appeared in a Barclays question about U.K. captive‑reinsurance rules. Porter said the proposed PRA changes would likely compress economics for ceding companies but would also heighten the value of strong counterparties like RGA, which conducts most of its U.K. longevity business on a swap basis, thereby limiting exposure to the new charges.

A potential sidecar vehicle for long‑term care and universal‑life guarantees resurfaced in a Dowling Partners query. André confirmed that RGA is still focused on deploying the Ruby Re sidecar, with the final block of capital awaiting investor approval. He declined to give a timeline but suggested that “it is too early to be specific” as the firm concentrates on completing Ruby Re’s deployment.

The market reacted modestly. RGA shares slipped 0.83% to $212.81 in after‑hours trading, keeping the stock 7.2% below its 52‑week high but still up 4.6% year‑to‑date. The modest pullback reflects investor caution over the capital‑deployment outlook rather than any fundamental disappointment.

Overall, RGA’s Q1 narrative blends solid earnings, favorable claims, and a disciplined capital‑return program with a forward‑looking challenge: converting a robust pipeline into the scale of deployments required to sustain double‑digit EPS growth. As the firm leans into its “strategic optionality” across Asia, Europe, and the U.S., investors will watch closely whether the next wave of in‑force blocks and sidecar capital can materialize without eroding the profitability margins that have defined the quarter.